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Nutritional status is critically important for immune cell function. While obesity is character-
ized by inflammation that promotes metabolic syndrome including cardiovascular disease
and insulin resistance, malnutrition can result in immune cell defects and increased risk
of mortality from infectious diseases. T cells play an important role in the immune adapta-
tion to both obesity and malnutrition. T cells in obesity have been shown to have an early
and critical role in inducing inflammation, accompanying the accumulation of inflammatory
macrophages in obese adipose tissue, which are known to promote insulin resistance.
How T cells are recruited to adipose tissue and activated in obesity is a topic of consid-
erable interest. Conversely, T cell number is decreased in malnourished individuals, and T
cells in the setting of malnutrition have decreased effector function and proliferative capac-
ity. The adipokine leptin, which is secreted in proportion to adipocyte mass, may have a
key role in mediating adipocyte-T cell interactions in both obesity and malnutrition, and has
been shown to promote effector T cell function and metabolism while inhibiting regula-
tory T cell proliferation. Additionally, key molecular signals are involved in T cell metabolic
adaptation during nutrient stress; among them, the metabolic regulator AMP kinase and
the mammalian target of rapamycin have critical roles in regulatingT cell number, function,
and metabolism. In summary, understanding how T cell number and function are altered
in obesity and malnutrition will lead to better understanding of and treatment for diseases
where nutritional status determines clinical outcome.
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NUTRITIONAL STATUS ALTERS T CELL IMMUNITY
Both obesity and malnutrition are major health problems around
the globe. The World Health Organization has listed both obe-
sity/overweight and childhood malnutrition/underweight on its
top 10 causes of global mortality and disease. In developed coun-
tries, there has been an emphasis on the deleterious health effects of
obesity. Obesity is associated with life-threatening co-morbidities
including cardiovascular disease and type 2 diabetes that shorten
lifespan. However, we must remember that for the majority of
the world population, malnutrition from chronic food depriva-
tion is the more common nutritional problem. Both obesity and
malnutrition are associated with changes in immune cell num-
ber and function that alter immunity and have consequences for
infection and inflammation. In this review, we will discuss the
effects of nutrition on T cell distribution and function and exam-
ine the role of T cells in altered immunity in both malnutrition
and obesity.
OBESITY AND INFLAMMATION
Obesity is a growing epidemic in developed countries. For exam-
ple, over 30% of Americans are currently classified as overweight or
obese (1). Unfortunately, the obesity epidemic is accompanied by a
myriad of associated health risks. Exacerbating the problem is the
absence of safe and effective treatments to reverse obesity. Lifestyle
modifications such as diet and exercise are oftentimes ineffective,
and at present, bariatric surgery is the most effective treatment
for obesity but can be associated with post-surgical complications
and side effects.
Obesity is associated with life-threatening co-morbidities such
as insulin resistance leading to type 2 diabetes mellitus, as part of
the metabolic syndrome (2). Indeed, the prevalence of both obe-
sity and diabetes has increased in parallel during the last 20 years,
and is highly associated (3). From these trends, the United States
Centers for Disease Control (CDC) predicts that 1 in 3 Amer-
ican adults will have diabetes by the year 2050 (4). As part of
the metabolic syndrome, obese individuals are also at risk for
hyperlipidemia and hypertension leading to increased cardiovas-
cular and renal disease. Additionally, obesity increases the risk of
multiple forms of autoimmunity (5–7), including multiple scle-
rosis (MS), thyroid autoimmunity, and type 1 diabetes. Obesity
is further associated with an increased risk of certain forms of
cancer, including esophageal, breast, endometrial, colorectal, kid-
ney, pancreatic, gallbladder, and thyroid cancer (8, 9). And finally,
obese individuals have increased susceptibility to infections due
to impaired host defense (10). In fact, obese individuals were
more susceptible to the pandemic H1N1 influenza outbreak of
2009 (11).
Obesity is associated with both systemic inflammation and an
influx of pro-inflammatory immune cells into visceral adipose tis-
sue (VAT) (12). These VAT-localized immune cells secrete inflam-
matory cytokines, which have been shown to promote insulin
resistance (12, 13). It is now clear that T lymphocytes (T cells),
in particular, have a critical role in the early stages of this inflam-
matory process. Both regulatory and inflammatory T cells are
found in VAT and influence the recruitment and function of other
inflammatory cells into VAT, thereby contributing to changes in
www.frontiersin.org August 2014 | Volume 5 | Article 379 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gerriets and MacIver T cells in malnutrition and obesity
FIGURE 1 | Adipose tissue is remodeled following high-fat
diet-induced obesity. Multiple immune cells reside in adipose tissue.
High-fat diet-induced obesity results in decreased regulatory T cells (Treg)
and alternatively activated M2 macrophages. At the same time, there is an
increase in adipose-resident inflammatory macrophages (classically
activated M1 macrophages), CD4+Th1 cells, CD8+T cells, and B cells.
The role of CD4+Th2 and Th17 cells in adipose tissue in obesity is less
certain.
insulin sensitivity in obesity (Figure 1). For these reasons, it is crit-
ically important to determine how obesity and increased adiposity
alter T cell distribution and function to drive inflammation.
EARLY STUDIES ON OBESITY-RELATED INFLAMMATION
In the 1990s, several observations were made that first linked obe-
sity with inflammation. A key early study by Hotamisligil et al.
demonstrated that expression of the pro-inflammatory cytokine
tumor necrosis factor alpha (TNF-α) was increased in the adi-
pose tissue of obese animals (14). Moreover, loss of TNF-α in
obesity resulted in improved insulin sensitivity and glucose home-
ostasis (14–16). Not long after these initial findings with TNF-α,
other pro-inflammatory cytokines were implicated. In a prospec-
tive study in 2001, both C-reactive protein (CRP) and IL-6 were
found to be predictive of the development of type 2 diabetes in
obese patients (17).
Soon after, macrophages were identified as an inflammatory
cell of interest in obesity-associated inflammation. In 2003, it was
discovered that many macrophage-specific genes were upregulated
in both genetic and diet-induced forms of obesity in animals (18,
19). Around the same time, macrophages were found to accu-
mulate in adipose tissue in obese animals (19). A few years later,
macrophages in obese adipose tissue were ascribed an inflamma-
tory phenotype that differs from the phenotype of macrophages
in lean adipose tissue (20, 21).
These early studies have led to an understanding of mul-
tiple immune cells, chemokines, and cytokines contributing to
the network of inflammation leading to insulin resistance and
metabolic syndrome in obesity. Since these early studies, multiple
pro-inflammatory cells, in addition to macrophages, have been
ascribed a role in either promoting inflammation (lymphocytes,
mast cells, neutrophils, and NK cells) or regulating inflammation
(regulatory T cells) in obesity. Additionally, adipocytes themselves
can secrete pro-inflammatory cytokines, many of which overlap
with cytokines produced by macrophages, including TNF-α and
IL-6, as well as hormones that influence inflammation, such as
the pro-inflammatory hormone leptin and the anti-inflammatory
hormone adiponectin.
An important question remained, how do inflammatory
cytokines and signals promote insulin resistance? Elevated inflam-
matory signals were found to induce both c-Jun N-terminal kinase
(JNK) signaling pathways and activation of the inhibitor of nuclear
factor kappa-B (NF-κB) kinase subunit beta (IKKβ),which goes on
to promote NF-κB activation. Both JNK and IKKβ/NF-κB signal-
ing pathways were found to decrease insulin action of adipocytes
and hepatocytes (22, 23). Multiple studies have now shown that
blocking inflammatory cells or cytokine signaling in adipose tis-
sue prevents development of inflammation and subsequent insulin
resistance in obesity.
MACROPHAGES IN OBESITY-RELATED INFLAMMATION
Macrophages are present in both lean and obese VAT and, in fact,
make up 40–60% of VAT immune cells in obesity. The role of
the macrophage in VAT and promoting insulin resistance in obe-
sity is well studied and has been extensively reviewed (24, 25).
Interestingly, there is an overlapping biology and function of VAT-
localized macrophages and adipocytes, and these two cell types
produce many hormones and cytokines in common, including
inflammatory cytokines implicated in obesity-associated inflam-
mation and insulin resistance (26). These inflammatory cytokines
have paracrine effects on other adipose-localized cells and may be
secreted into circulation to exert endocrine effects systemically.
Macrophages are polarized toward either an M1 or M2 phe-
notype. Macrophages in lean tissue are typically M2 macrophages,
also known as“alternatively activated macrophages,” which secrete
anti-inflammatory cytokines, including IL-10, IL-1 receptor ago-
nist, and arginase-1. Obesity-associated VAT macrophages are
largely M1 macrophages, or “classically activated macrophages”
that secrete large amounts of inflammatory cytokines including
TNF-α, IL-6, IL-12, IL-1β, and monocyte chemotactic protein 1
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(MCP-1) (24). These M1 macrophages in obese VAT are either
derived from macrophages already present in adipose tissue, which
have changed their phenotype in response to obesity, or they are
recruited into adipose tissue from circulation. Obesity-associated
effects on VAT include the release of chemokines, such MCP-1.
MCP-1 binds to the chemokine (C–C motif) receptor 2 (CCR2) on
macrophages, and has been described to recruit macrophages into
adipose tissue in obesity (27). Many studies have demonstrated
the role for classically activated M1 macrophages in promoting
insulin resistance, and numerous mouse models have confirmed
that disabling the macrophage inflammatory response pathway in
obesity is protective against the development of insulin resistance
(25, 28).
In addition to macrophages, other innate immune cells appear
to participate in regulating inflammation and insulin resistance
in obesity. Both pro-inflammatory neutrophils and mast cells
are activated in obesity, and mice lacking these innate inflam-
matory cells are protected against insulin resistance (29). Con-
versely, eosinophil number is decreased in the VAT of obese mice,
and eosinophil-deficient mice have increased inflammation and
insulin resistance (29). While innate cells are clearly important to
regulate inflammation in obesity, we will not focus on the role
of the innate cells in obesity-associated inflammation and insulin
resistance here, but rather highlight the role of the lymphocyte.
LYMPHOCYTES IN OBESITY-RELATED INFLAMMATION
In 2009, Nature Medicine published a series of three papers that
altogether established a critical role for both inflammatory and
regulatory T cells in mediating adipose tissue inflammation and
altering insulin sensitivity in obesity (30–32). Together, these stud-
ies demonstrated that obesity was associated with T cell changes
in VAT that included decreased regulatory T cells (Treg) and
Th2 cells and increased inflammatory Th1 and CD8+ T cells.
Soon after, other studies confirmed a role for T cells in adi-
pose tissue in promoting systemic inflammation in obesity (33).
These reports established a potentially early and critical role for
inflammatory lymphocytes (CD8+ T cells, Th1 helper cells, and
B cells) and regulatory lymphocytes (Th2 helper cells and Treg)
in obesity-associated inflammation leading to insulin resistance.
Thus began a new era of investigation into the role of lympho-
cytes in obesity-associated inflammation. It soon became clear that
both the type and the proportion of lymphocytes and lymphocyte
subsets change in VAT in obesity. We will discuss findings regard-
ing lymphocyte subsets that either promote or down regulate
obesity-induced inflammation here.
PRO-INFLAMMATORY LYMPHOCYTES
CD4+ Th1 cells
VAT from high-fat diet-induced obese mice has higher levels
of both CD4+ and CD8+ T cells, as compared to lean con-
trols. T cells from obese VAT produce high levels of the Th1
cytokine interferon gamma (IFN-γ) when stimulated in vitro (34).
IFN-γ secreted from adipose tissue induces the polarization of
macrophages toward the M1 phenotype. IFN-γ also increases
the production of other inflammatory cytokines, including TNF-
α, from adipose tissue cultured in vitro. Obese animals lacking
IFN-γ expression produced less adipose TNF-α and MCP-1, had
decreased inflammatory cell accumulation in adipose tissue, and
had improved insulin sensitivity compared to animals with nor-
mal IFN-γ expression (34, 35). Most recently, Khan et al. examined
T cell receptor beta (TCRβ) deficient mice, which are protected
against obesity-induced macrophage infiltration and insulin resis-
tance, and found that adoptive transfer of Th1 cells into high-fat
diet-fed TCRβ-/- mice led to increased muscle and adipose tissue
inflammation as well as increased insulin resistance (36).
The T cell-specific T-box transcription factor, T-bet, which is
known to induce Th1 development and promote transactivation
of the IFN-γ gene, has also been implicated in obesity-associated
inflammation. T-bet knockout mice have decreased energy expen-
diture and increased visceral adiposity compared to wildtype litter-
mates, yet have better insulin sensitivity on both normal chow and
high-fat diet (37). While the T-bet knockout mice were expected to
have increased insulin sensitivity, the finding that they were more
obese, with increased visceral adiposity, was surprising, as obesity
and insulin resistance are typically co-associated. Improved insulin
sensitivity is perhaps due to decreased expression of Th1 cytokines
and increased expression of Th2 cytokines and the Th2 transcrip-
tion factor GATA binding protein 3 (GATA3) in the T-bet knockout
animal (38). Moreover, adoptive transfer of T-bet-deficient CD4+
T cells, but not wildtype CD4+ T cells, into Rag2-/- mice, which
lack both B and T lymphocytes, modestly improves insulin sensi-
tivity (37). As Th1 cells typically produce both T-bet transcription
factor and IFN-γ cytokine, their role in insulin sensitivity was
examined in IFN-γ knockout mice. Loss of T-bet on an IFN-γ
knockout mouse conferred no additional improvement to insulin
sensitivity (39).
CD4+ Th17 cells
The role of Th17 cells in VAT in obesity is less clear. In 2009,
Winer et al. described an association between obesity and IL-17
production in mice (40). IL-17 expression has also been found to
be high in obese human beings (41), and peripheral blood samples
from human beings with type 2 diabetes mellitus have increased
numbers of circulating Th17 cells (42, 43). Obesity can exacerbate
autoimmune diseases that have a strong Th17-dependent mech-
anism, including experimental autoimmune encephalomyelitis
(EAE) in mice, MS in human beings, and colitis (44). IL-17 has
been found to be produced by T cells in adipose tissue, and IL-17
knockout mice are overweight and have increased obesity fol-
lowing high-fat diet compared to littermate controls, but show
improved insulin sensitivity (45). However, IL-17 can be produced
by both Th17 cells and gamma delta (γδ) T cells and appears to be
secreted from γδ T cells in VAT (45). One group has even reported
IL-17 production from neutrophils in obesity (46). Therefore, the
role of Th17 cells in inflammation and insulin resistance in obesity
remains uncertain.
CD8+ T cells
Obesity is associated with increased CD8+T cells in adipose tissue
(47). In 2009, Nishimura et al. demonstrated that CD8+ T cells
preceded macrophages into VAT in obesity (30). Moreover, deple-
tion of CD8+ T cells in diet-induced obesity resulted in decreased
accumulation of macrophages into obese VAT as well as improved
insulin sensitivity. Conversely, adoptive transfer of CD8+ T cells
www.frontiersin.org August 2014 | Volume 5 | Article 379 | 3
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Gerriets and MacIver T cells in malnutrition and obesity
into CD8-deficient mice increased infiltration of macrophages
into VAT as well as expression of the inflammatory cytokines IL-6
and TNF-α, along with development of insulin resistance follow-
ing high-fat diet (30). These findings suggest a critical role for
CD8+ T cells in the development of inflammation and insulin
resistance in obesity. More recently, Jiang et al. confirmed VAT
accumulation of CD8+ T cells in obesity and examined the mech-
anism of CD8+ T cell accumulation in adipose tissue (48). The
authors found that VAT CD8+ T cells are activated in vitro by Th1
cytokine IFN-γ. Moreover, CD8+ T cells from VAT in obese mice
expressed high levels of the integrin CD11a, which was important
for infiltration of CD8+ T cells into adipose tissue in obesity (48).
B cells
In addition to increased CD4+ and CD8+ T cells, B cells also
accumulate in VAT in diet-induced obesity (49). Diet-induced
obese mice that lacked B cells, following treatment with B cell
depleting CD20 antibody, were protected against insulin resis-
tance, despite weight gain on a high-fat diet (50). Treatment of
these B cell-deficient mice with IgG from wildtype obese mice
resulted in restoration of insulin resistance (50). These findings,
therefore, establish a role for both B cells and IgG antibodies in
driving insulin resistance in obesity. In recent work from a sep-
arate group, cytokine production was compared in obesity from
B cell null mice and wildtype controls. Obese B cell null mice
had decreased inflammatory cytokines, including IL-6 and IFN-γ,
increased anti-inflammatory IL-10 levels, and protection against
insulin resistance compared to obese wildtype mice (51). Absence
of B cells in obesity was also associated with an increased number
of regulatory T cells (Treg) in VAT, as compared to obese wildtype
mice. Additionally, human B cells from type 2 diabetics, but not
from non-diabetic controls, were able to activate T cells in vitro
(51). These results suggest a possible mechanism in which B cells
precede T cells, and possibly macrophages, into VAT and regulate
T cell differentiation, inflammation, and activation in obesity.
LYMPHOCYTES WITH AN ANTI-INFLAMMATORY ROLE IN OBESITY
Regulatory T cells (Treg) have been found to have a key role in
the regulation of inflammation and the development of insulin
resistance in obesity. Obese human beings have decreased circu-
lating Treg cells (52), and genetic mouse models of obesity and
diet-induced obese mice show decreased Treg numbers in VAT
(31). When Treg cells were depleted acutely, investigators observed
increased transcription of inflammatory genes in VAT along with
increased insulin levels and decreased insulin receptor signaling
(31). This suggests that Treg play an important role to suppress
obesity-related inflammation. Indeed, expansion of the Treg com-
partment in high-fat diet-fed mice was associated with increased
levels of IL-10, statistically significant lower blood glucose levels,
and trends toward lower insulin resistance and glucose tolerance
(31).
In 2012, Cipolletta et al. described peroxisome proliferator-
activated receptor gamma (PPAR-γ) expression as a critical player
in Treg accumulation in VAT and in insulin sensitivity (53).
PPAR-γ expression was increased in VAT Treg as compared to
peripheral lymphoid Treg cells, and establishment of VAT Tregs
from naïve CD4+ T cells depended on both PPAR-γ and Foxp3
expression. Indeed, conditional knockout of PPAR-γ in Treg
resulted in decreased Treg number in VAT but did not affect
Treg number in peripheral lymphoid tissue (53). PPAR-γ is well
known to influence adipocyte differentiation and is considered
anti-inflammatory. Members of the class of drugs called thia-
zolidinediones are PPAR agonists, and have been used in the
treatment of type 2 diabetes mellitus for many years, although
their use over the past five years has been limited due to car-
diovascular side effects and outcome. The authors of this study
found that PPAR-γ expression was required for action of the thi-
azolidinedione drug pioglitazone to restore insulin sensitivity in
obesity, as pioglitazone enhanced the accumulation of VAT Treg
and improved insulin sensitivity in obese mice (53). These findings
suggest a novel mechanism by which PPAR agonists can promote
insulin sensitivity through the regulation of T cell differentiation
and function, as opposed to modulation of PPAR expression in
adipocytes. Moreover, these findings highlight Treg as an interest-
ing potential drug target of obesity-related inflammation and type
2 diabetes mellitus.
More recently, Han et al. described a key role for insulin in regu-
lating Treg function (54). The authors found that insulin receptors
are expressed on Treg,and that insulin signaling directly influenced
Treg function by decreasing IL-10 production via activation of the
AKT/mammalian target of rapamycin (mTOR) signaling pathway
(54). Insulin was also able to reduce Treg suppression of TNF-α
production by macrophages. When Treg were isolated from obese
or lean VAT in mice, Treg from obese VAT produced less IL-10
and more IFN-γ than Treg from lean animals (54). These find-
ings suggest that increased insulin levels in obesity can promote
inflammation by directly reducing Treg suppression and thereby
driving the chronic inflammation of obesity.
MIGRATION AND ACTIVATION OF T CELLS IN VAT IN OBESITY
While the presence of inflammatory T cells in adipose tissue
is now well established, the mechanism by which T cells are
recruited into obese VAT and how they are activated has been
less clear. Recent publications have started to address these ques-
tions. The chemokine receptor CXCR3 has recently been found
to have a critical role in T cell recruitment into VAT in obe-
sity. CXCR3 knockout mice on high-fat diet had fewer VAT T
cells than wildtype mice on high-fat diet (55). Obese CXCR3
knockout mice also developed less insulin resistance follow-
ing 8 weeks of high-fat diet compared to wildtype obese mice,
although this protection was lost by 16 weeks. The diet-induced
obese CXCR3 knockout mice also expressed lower levels of mRNA
for several pro-inflammatory genes including MCP-1 in adipose
tissue, and higher levels of anti-inflammatory genes, including
Foxp3 and IL-10 (55). A separate group also examined CXCR3
knockouts on high-fat diet for 20 weeks. They observed simi-
lar weight gain in CXCR3-/- and wildtype mice, but observed
decreased fasting glucose and improved glucose tolerance in
CXCR3 knockouts, along with decreased infiltration of imma-
ture myeloid cells into VAT (56). Other chemokine systems may
also play a role in this process. Expression of the chemoattrac-
tant RANTES is induced in adipocytes in obesity along with
its chemokine receptor CCR5 (57, 58). CCR5 also has a criti-
cal role in obesity-associated inflammation as CCR5 knockout
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mice on high-fat diet demonstrate a shift from pro-inflammatory
M1 to M2 macrophages in VAT, and are protected against insulin
resistance in obesity (58).
Once T cells are recruited to adipose tissue in obesity, they
require activation to maintain a pro-inflammatory state. There
is evidence for both macrophages and B cells (51, 59), as well as
adipocytes (60), in acting as antigen-presenting cells to stimulate
T cell activation and inflammation of VAT in obesity. Adipocytes
certainly secrete hormones and cytokines that are well known to
promote inflammatory T cell activation, including leptin, resistin,
TNF-α, and IL-6. Additionally, adipocyte-derived lipids have been
shown to modulate T cell function (60). However, in addition
to secreting cytokines, hormones, and lipids that can influence T
cell inflammation, adipocytes may also serve as antigen-presenting
cells by expressing MHC class II and co-stimulatory membrane
receptors on their surface, thereby activating CD4+ T cells (61).
TARGETING T CELL INFLAMMATION IN THE TREATMENT OF INSULIN
RESISTANCE
Understanding the role of lymphocyte inflammation in promot-
ing insulin resistance in obesity opens up new possibilities for
treatment of type 2 diabetes. Weight loss has been shown to
both decrease inflammatory cytokine production and improve
insulin sensitivity (62). Even exercise alone has been shown to
reduce inflammatory cells in VAT in obesity (63). However, as
stated above, weight loss through lifestyle modifications of diet
and exercise is challenging for many and oftentimes unsuccessful.
In addition, new evidence supports the idea that weight loss may
be harder to achieve in an inflammatory state. In a recent report
published in The Journal of Clinical Endocrinology and Metabo-
lism in 2014, the presence of increased inflammation, as measured
by inflammatory cytokine levels, prior to bariatric surgery, led
to decreased body mass index reduction following weight-loss
surgery (64).
Subsequently, the idea of immunotherapy in the treatment
of type 2 diabetes had gained considerable interest. Thus far,
there have been a handful of targets of inflammation that have
shown therapeutic promise for the treatment of diabetes. The
first is TNF-α blockade, which has shown some mixed success
in improving insulin resistance in diabetic patients (65–67). The
second target of interest is NF-κB activation blockade. Early-
animals studies in 2001 showed that salicylates could reverse
obesity-associated insulin resistance in both genetically obese and
diet-induced obese mice (68, 69), which resulted in decreased
NF-κB activation. In a more recent series of studies, salicylates
were found to be potentially useful for the treatment of high-fat
diet-induced insulin resistance in diabetes in human subjects (70),
yet results are mixed (71), and blockade of NF-κB is very down-
stream in the VAT inflammatory pathway in obesity, so inflamma-
tory cell numbers are not typically affected (13). Finally, there is
some evidence that selective blockade of IL-1 receptor activation
may prevent insulin resistance in obesity-associated inflamma-
tion (72). A more recent study investigated the effect of T cell
co-stimulation blockade on obesity-associated insulin resistance,
and found that both CD40L antibody and cytotoxic T lymphocyte
antigen 4 (CTLA-4) immunoglobulin (Ig)-treated diet-induced
obese mice had reduced numbers of VAT macrophages and CD8+
T cells, as compared to obese mice treated with control antibody
(73). However, only the CD40L antibody-treated, and not the
CTLA-4 Ig-treated mice, had decreased weight gain and subse-
quent improvement in insulin sensitivity. Altogether, modulation
of obesity-associated inflammation is of considerable interest at
present, and may offer novel therapeutic targets for type 2 diabetes
in obesity.
MALNUTRITON AND IMMUNODEFICIENCY
Like obesity, malnutrition is a serious global health issue affecting
many. In 2011, it was estimated that over 52 million children were
severely malnourished (74). This has important health implica-
tions,as children that are malnourished have suppressed immunity
and higher mortality due to infections (75–77). Childhood mal-
nutrition is also associated with impaired cognitive development,
as well as persistent defects in learning and memory (78, 79).
Young children and infants are particularly at risk, as 45% of
deaths in children under age five years are due to undernutrition
(74). Malnutrition specifically accounts for 2.6 million childhood
deaths annually due to infections including diarrheal illness and
pneumonia (80, 81).
In addition to chronic malnutrition in developing countries,
malnutrition can also affect immune function in other clinical
settings in which nutritional status influences outcome. Such sce-
narios include patients with cancer- and AIDS-related cachexia,
critically ill ICU patients, and low birth weight neonates with
inadequate adipose stores. In fact, it is estimated that 60–80% of
patients with advanced cancer are cachexic, and weight loss prior
to chemotherapy greatly increases mortality in cancer patients
(82, 83). Additionally, the U.S. National Cancer Institute has esti-
mated that up to 40% of cancer deaths result from infections
related to malnutrition. Malnutrition-induced immune suppres-
sion is, therefore, a major cause of morbidity and mortality in
multiple susceptible patient populations. Despite an abundance
of epidemiological evidence linking malnutrition and immun-
odeficiency, little is known about the impact of malnutrition
on specific immune cell populations. Here, we describe recent
findings on the role of malnutrition on lymphocyte number
and function.
MALNUTRITION AND T CELLS
Malnutrition has been linked to immune dysfunction in a vari-
ety of settings, including starvation and cachexia in both human
beings and mice (77, 80–82). As T cells are a vital component
of the adaptive immune system, several studies have specifically
examined the effect of malnutrition on T cell number and func-
tion. Mice fasted for 48 h had drastically decreased thymocyte
and splenocyte counts compared to fed-control mice (84–86).
Within the spleen, total T cell and CD4+ T cell numbers from
fasted mice were decreased by 40–50% compared to control ani-
mals (85, 86). Additionally, mice fed a protein-deficient diet had
atrophic spleens and decreased T cell numbers compared to con-
trol mice (87, 88). Decreased T cell numbers observed in fasted
mice are mimicked in malnourished human beings. Malnourished
children had decreased CD4+ and CD8+T cell numbers in whole-
blood samples compared to T cell numbers from well-nourished
children (89).
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In addition to drastically reducing T cell numbers, malnutrition
also affects T cell cytokine production. Protein energy malnutri-
tion impaired the ability of rat lymphocytes to proliferate and
produce the Th1-associated cytokine IFN-γ (90). Similarly, T cells
from mice that were fasted for 48 h and then activated in vitro
had greatly decreased production of the Th1 cytokines IL-2 and
IFN-γ, compared to T cells from fed control animals (86). This
decrease in cytokine production observed in malnourished mice
was also observed in human studies, as malnourished children had
decreased levels of cytokines important for Th1 differentiation
(IL-12, IL-18, and IL-21) as well as decreased Th1 cytokines IFN-γ
and IL-2 (91). In a separate study, the same group showed that
malnourished children had increased expression of Th2 cytokines
IL-4 and IL-10 (92). Altogether, these findings suggest that mal-
nutrition shifts the balance of pro-inflammatory Th1 versus anti-
inflammatory Th2 cytokines, and may offer an explanation as to
how malnutrition predisposes to infection.
Upon activation, effector T cells undergo metabolic reprogram-
ming that results in transition from an oxidative state to a highly
glycolytic phenotype. Accompanying this metabolic switch is an
increase in expression of the ubiquitous glucose transporter, Glut1,
which leads to increased glucose uptake and subsequent glycolysis
(93, 94). This shift from oxidative to glycolytic metabolism is crit-
ical to maintain T cell function, as decreased glucose availability
inhibits T cell cytokine production and proliferation (93, 95). We
have found that acute malnutrition inhibits activation-induced T
cell glucose metabolism (86). Rescue of this metabolic defect with
T cell-specific overexpression of a Glut1 transgene normalizes glu-
cose uptake to levels in T cells from fed controls. Additionally,
Glut1 overexpression returns inflammatory cytokine production
back to levels seen in T cells isolated and activated from fed mice,
suggesting that rescue of T cell glucose metabolism reverses the T
cell functional defects seen in malnutrition (86). This leads to the
intriguing possibility that decreased circulating glucose levels in
fasting may directly affect T cell metabolism and, therefore, T cell
function. Indeed, anti-CD3 antibody treatment to activate T cells
in vivo led to an increase in T cell glucose uptake and a marked
decrease in circulating glucose levels, resulting in hypoglycemia in
mice (96). Hypoglycemia following anti-CD3 antibody treatment
did not occur in Rag1-/- mice that lack lymphocytes (96). This
suggests that T cells utilize a substantial amount of glucose during
activation and may be affected by altered circulating glucose levels
due to starvation or malnutrition. More work is needed to gain a
complete understanding of the relationship between malnutrition,
T cell metabolism, and function.
MALNUTRITION AND INFECTION
Increasing evidence suggests that malnutrition can lead to more
severe viral infections and can affect vaccine responses in children
(76, 97). Although most epidemiological studies examined general
nutrient deficiencies, many of the animal studies specifically assess
the effect of protein energy malnutrition (PEM) on viral immu-
nity, using low-protein or protein-deficient diets in mouse models
(87, 88, 98, 99). In a respiratory infection model, mice fed a low-
protein diet required a 1000-fold lower viral titer for 50% lethality
than normal fed controls (87). Similarly, malnourished mice inoc-
ulated with Mycobacterium tuberculosis had 2–3 logs more bacilli
in the lungs than mice receiving a full protein diet (100). PEM also
increased the susceptibility to influenza infection due to impaired
viral clearance and decreased lymphocyte numbers (88). Impor-
tantly, supplementation with protein enhanced viral clearance and
decreased mortality from influenza (88).
Furthermore, PEM impaired the homeostatic proliferation of
mouse memory CD8+ T cells in response to lymphocytic chori-
omeningitis virus (LCMV) (98). A separate group showed a
decreased number of viral-specific CD8+ T cells upon protein
malnutrition during LCMV infection (99). The low-protein diet
impaired the recall response and maintenance of memory CD8+T
cells; this could be rescued by protein supplementation, suggesting
that dietary protein is critical for maintaining a functional pool of
memory T cells (98). This defect in CD8+ T cell function during
malnutrition also occurs in human beings. Malnourished children
hospitalized with bacterial infections were shown to have a lower
fraction of memory T cells than well-nourished infected controls
(101), as well as decreased total CD4+ and CD8+ T cell num-
bers (89). Together, these data suggest that malnutrition decreases
CD8+ T cell number and function and predisposes to infection.
MALNUTRITION AND AUTOIMMUNITY
As malnutrition reduces T cell number and function, there is
increasing evidence that calorie-restriction and fasting protect
against autoimmune disease. One study examined BXSB mice,
which spontaneously develops an autoimmune disease similar
to systemic lupus erythematosus (SLE) (102). A 40% calorie-
restriction inhibited the onset of autoimmunity and increased
the lifespan of mice compared to those on a non-restricted
diet (103). The calorie-restricted mice also had decreased IL-
2 production and lymphocyte proliferation compared to con-
trols (103). Piccio et al. examined a 40% calorie-restriction in
the context of two EAE models. In both EAE models, calorie-
restriction increased survival and decreased disease scores dur-
ing EAE progression (104). Additionally, calorie-restriction sig-
nificantly decreased central nervous system inflammation and
demyelination as well as plasma levels of the pro-inflammatory
cytokine IL-6 (104). A separate group showed that mice fasted for
48 h had decreased EAE disease scores as well as decreased IFN-γ
production (105). Similar findings were also shown in calorie-
restricted rats (106). Interestingly, mice fed ad libitum every other
day (intermittent feeding) also developed less severe EAE com-
pared to control animals fed ad libitum (107). Together, these
data suggest that calorie-restriction and fasting prevent autoim-
munity, likely by decreasing T cell responses and inflammatory
cytokine production.
ROLE OF LEPTIN IN MEDIATING NUTRITIONAL EFFECTS
ON T CELLS
Leptin is an adipokine secreted in proportion to adipocyte mass.
In addition to its well-described role in regulating appetite, energy
expenditure, and body weight, leptin is also a pro-inflammatory
cytokine. Leptin has direct and indirect effects on T cell number
and function, promoting Th1 and Th17 cell number and cytokine
production while inhibiting Th2 cytokine production and Treg
proliferation (108). The effects of leptin on T cell number and
function have been extensively reviewed and will not be discussed
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in depth here, yet special consideration must be given to the role
of leptin in mediating T cell changes in malnutrition or obesity.
Acute starvation causes a drastic reduction in leptin levels in
both mice and human beings; indeed, many studies utilize fasting
as a way to model hypoleptinemia in mice (84–86). Low levels
of leptin are associated with high rates of death from infectious
diseases (109, 110). In a recent study published in the Journal of
Clinical Endocrinology and Metabolism, the hormonal and meta-
bolic status of malnourished Ugandan children was examined. In
this study, low leptin levels were found to be the single most impor-
tant biomarker to predict mortality during inpatient treatment of
malnutrition (111).
Additionally, leptin-deficient ob-/- mice, despite their genetic
obesity, have many features similar to those seen in malnutri-
tion, including decreased body temperature, infertility, and low
metabolic rate (112). Ob-/- mice also have immune defects sim-
ilar to those seen in malnourished human beings and animals,
including decreased thymocyte and splenocyte numbers, increased
susceptibility to infection, and protection against certain forms
of autoimmunity (84). Both the metabolic and immune defects
seen in ob-/- mice can be reversed by treatment with recombinant
leptin.
A role for leptin in reversing malnutrition-induced immuno-
suppression has been examined by our group and others. Although
fasting leads to decreased T cell number and function, these defects
can be reversed by treatment with recombinant leptin during the
period of starvation (85, 86). Either leptin administration to fast-
ing mice in vivo or leptin treatment of T cells isolated from fasted
animals in vitro was sufficient to rescue inflammatory cytokine
production in activated T cells from fasted mice (86). Impor-
tantly, leptin also rescued the T cell metabolic defects seen in
fasting. Leptin treatment led to increased Glut1 expression and
increased glucose uptake and glycolysis in fasted animals (86).
Leptin is, therefore, a critical regulator of T cell glucose metabo-
lism to fuel T cell activation. In other studies, leptin replacement
was found to reverse starvation-induced immunosuppression,
as measured by a delayed-type hypersensitivity (DTH) response
(113), and prevented starvation-induced protection against EAE
(105). Together, these data suggest that leptin is an important mod-
ulator of nutritional effects on T cell metabolism and function
(Figure 2).
Leptin itself or the regulatory pathways that control leptin
expression or action may be important new targets to promote
immunity (114). In a small clinical study of malnourished chil-
dren hospitalized for infection in Mexico, treatment of peripheral
blood T cells with leptin in vitro increased T cell activation and
inflammatory IL-2 and IFN-γ cytokine production, while decreas-
ing IL-4 and IL-10 production (115). Additionally, leptin has been
used as a mucosal vaccine adjuvant for Rhodococcus equi bacte-
rial infections in mice, and leptin signaling was also associated
with higher Helicobacter pylori antibody titers following vacci-
nation (116, 117). Understanding the pathways by which leptin
regulates T cell metabolism and function may lead to new ways
to augment immunity in select clinical disorders associated with
undernutrition.
Conversely, the fact that leptin is a pro-inflammatory cytokine
secreted by adipocytes, in proportion to adipocyte mass, points to
a role for leptin in obesity-associated inflammation and insulin
resistance, and many have speculated on the role for leptin in pro-
moting inflammation in obesity. This is complicated, however, by
the fact that both the leptin-deficient and leptin receptor-deficient
ob-/- and db-/- mice, respectively, still develop insulin resistance in
the setting of genetic obesity (118). As leptin acts on every cell in
the immune system as well as stromal cells that influence immune
cell development, the direct effect of leptin on lymphocyte and
macrophage inflammation in obesity remains unclear.
NUTRIENT-SENSING T CELL SIGNALING
Key molecular signals are involved in T cell metabolic adapta-
tion during nutrient stress; among them, the metabolic regu-
lator AMP-activated protein kinase (AMPK) and its upstream
kinase, liver kinase B1 (LKB1), have critical roles in regulating
FIGURE 2 | Malnutrition leads to changes in adipocyte-secreted
hormones andT cell number and function. Malnutrition leads to decreased
adipocyte mass, which results in decreased circulating leptin. Concurrently,
malnourished individuals show changes in CD4+ and CD8+T cell number
and function, leading to increased susceptibility to infection and protection
against certain forms of autoimmunity. Leptin may mediate a subset of these
malnutrition-related changes to T cell number and function, as leptin is known
to alter CD4+T cell number and cytokine production.
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T cell number, function, and metabolism (119). AMPK is a
well-described metabolic regulator that responds to energy stress
and depletion of ATP reserves. AMPK is maximally active when
bound to AMP and phosphorylated by an upstream kinase,
typically LKB1. In select tissues, AMPK may also be phos-
phorylated by alternative kinases, including calcium/calmodulin-
dependent protein kinase kinase 2 (CaMKK2), which is responsive
to changes in intracellular Ca2+ concentration (120). In fact, in
T cells, activation of AMPK via phosphorylation by CaMKK2
occurs following TCR activation, presumably in anticipation of
the increased energy demands of activation (120). AMPK acti-
vation leads to increased energy-producing/catabolic pathways
while inhibiting energy-consuming/anabolic pathways. Interest-
ingly, the diabetic drug metformin activates AMPK, which leads
to improved insulin sensitivity and increased glucose uptake in
metabolic cells.
We and others have found that LKB1 is a central regulator
of T cell number, activation, and metabolism (121–123). T cell
knockout of LKB1 resulted in blocked thymocyte development
and decreased numbers of both CD4+ and CD8+ T cells. LKB1-
knockout T cells had defects in both viability and proliferation, as
well as increased expression of inflammatory cytokines IFN-γ and
IL-17 and increased glucose metabolism (121). AMPK-knockout
reproduced only a portion of the defects seen in the LKB1-
knockout mouse. Loss of T cell AMPK did not alter thymo-
cyte development or T cell number, but did result in increased
expression of inflammatory cytokines as well as increased glu-
cose metabolism. Increased mTOR complex 1 (mTORC1) sig-
naling in both AMPK- and LKB1-knockouts, contributed to the
phenotype (121).
The nutrient-sensing mTOR pathway is also important for
cellular nutrient/energy sensing and drives inflammatory T cell
differentiation and function. T cell specific knockout of mTOR
kinase to delete both mTORC1 and mTORC2 suppresses effector
T cell generation but allows Treg differentiation (124). The specific
contribution of mTORC1 activity to Treg function appears to be
complex. Deletion of mTORC1 activity has been shown to prevent
Treg suppressive function in some settings, and not affect Treg in
FIGURE 3 | Nutritional status is critical for normal immune function.
Malnutrition reduces immunity and increases markedly the risks and
mortality from severe infections, whereas obesity heightens immune
reactivity and predisposes to systemic inflammation that fosters the
development of inflammatory disorders and insulin resistance leading to
type 2 diabetes mellitus.
others (125, 126). AMPK has also been shown to promote Treg cell
function while inhibiting signaling pathways, including mTORC1,
which promote effector T cell differentiation, particularly Th1 and
Th17 (127). The role of the nutrient-sensing mTOR and AMPK
pathways on T cells in malnutrition, therefore, may be to act as
metabolic checkpoints so that inflammatory T cell expansion is
limited when nutrient availability is low. In the context of obesity,
adipokines such as leptin may promote mTOR activity to promote
effector T cell generation and contribute to inflammation (85).
CONCLUSION
In summary, T cell number, function, and metabolism are signifi-
cantly affected by nutritional status. Whereas malnutrition lowers
T cell number and metabolism and increases susceptibility to
infection, obesity increases inflammatory T cell numbers in VAT
and promotes systemic inflammation (Figure 3). Understanding
how T cells are altered in obesity and malnutrition will lead to bet-
ter understanding of and treatment for diseases where nutritional
status determines clinical outcome. Targeting the inflammatory
T cell response in obesity offers novel therapeutic options for
insulin resistance and type 2 diabetes, whereas augmenting T cell
response in malnutrition may promote immunity in clinical sce-
narios where malnutrition leads to poor outcome. Such scenarios
could include augmenting vaccine response in malnourished chil-
dren from underdeveloped countries and protecting chronically
ill patients with cachexia against infection. An understanding of
nutritional effects on T cells is therefore critically important for
public and global health.
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